Increased teicoplanin doses are associated with improved serum levels but not drug toxicity

Journal of Infection

Volumn 68, Issue 1, 2014, Pages 43-49

  Matthews, Philippa C ^a,b,c   Chue, Amy L ^a,b   Wyllie, David ^a,b   Barnett, Adam ^d   Isinkaye, Tomide ^b   Jefferies, Lorrayne ^a,e   Lovering, Andrew ^f   Scarborough, Matthew ^a,b  

^a NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e OXFORD HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^f SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Adverse effects; Glycopeptides; OPAT; Osteomyelitis therapy; Therapeutic drug monitoring

Indexed keywords

TEICOPLANIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHIL COUNT; EOSINOPHILIA; FEMALE; FEVER; GRAM POSITIVE INFECTION; HUMAN; KIDNEY INJURY; LEUKOPENIA; LIVER FUNCTION TEST; LOADING DRUG DOSE; MALE; MIDDLE AGED; NAUSEA; NEPHROTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; RASH; RETROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VERY ELDERLY; VOMITING; YOUNG ADULT;

ADVERSE EFFECTS; GLYCOPEPTIDES; OPAT; OSTEOMYELITIS THERAPY; THERAPEUTIC DRUG MONITORING;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TEICOPLANIN; YOUNG ADULT;

EID: 84888861494     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.08.018     Document Type: Article

References (23)

1. Scheinfeld N. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus. J Drugs Dermatol 2007, 6(1):97-103.
2. Harding I., Sorgel F. Comparative pharmacokinetics of teicoplanin and vancomycin. J Chemother 2000, 12(Suppl. 5):15-20.
3. Lemaire X., Loiez C., Valette M., Migaud H., Dubreuil L., Yazdanpanah Y., et al. Comparison of vancomycin and teicoplanin trough serum levels in patients with infected orthopedic devices: new data for old therapies. J Infect Chemother 2011, 17(3):370-374. 10.1007/s10156-010-0176-z.
4. Svetitsky S., Leibovici L., Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 2009, 53(10):4069-4079.
5. Janknegt R. Teicoplanin in perspective. A critical comparison with vancomycin. Pharm Weekbl Sci 1991, 13(4):153-160.
6. Cavalcanti A.B., Goncalves A.R., Almeida C.S., Bugano D.D., Silva E. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev 2010, 6:CD007022. 10.1002/14651858.CD007022.pub2.
7. Hahn-Ast C., Glasmacher A., Arns A., Muhling A., Orlopp K., Marklein G., et al. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?. Infection 2008, 36(1):54-58. 10.1007/s15010-007-7126-4.
8. Hung Y.P., Lee N.Y., Chang C.M., Lee H.C., Wu C.J., Chen P.L., et al. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review. Clin Ther 2009, 31(9):1977-1986. 10.1016/j.clinthera.2009.09.010.
9. Wilson A.P. Comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents 1998, 10(2):143-152.
10. Matsumoto K., Kanazawa N., Ikawa K., Fukamizu T., Shigemi A., Yaji K., et al. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections. J Infect Chemother 2010, 16(3):193-199. 10.1007/s10156-010-0038-8.
11. Brink A.J., Richards G.A., Cummins R.R., Lambson J. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. Int J Antimicrob Agents 2008, 32(5):455-458. 10.1016/j.ijantimicag.2008.05.012.
12. Tobin C.M., Lovering A.M., Sweeney E., MacGowan A.P. Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service. J Antimicrob Chemother 2010, 65(10):2155-2157.
13. Wilson A.P., Gruneberg R.N., Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 1994, 4(Suppl. 1):1-30.
14. MacGowan A.P., White L., Reeves D., Harding I. Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome. J Infect Chemother 1996, 2(4):197-208.
15. British national formulary 2012, Pharmaceutical Press. 63rd Revised ed.
16. Matthews P.C., Taylor A., Byren I., Atkins B.L. Teicoplanin levels inbone and joint infections: are standard doses subtherapeutic?. J Infect 2007, 55(5):408-413. 10.1016/j.jinf.2007.07.012.
17. Matthews P.C., Conlon C.P., Berendt A.R., Kayley J., Jefferies L., Atkins B.L., et al. Outpatient parenteral antimicrobial therapy(OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years. J Antimicrob Chemother 2007, 60(2):356-362. 10.1093/jac/dkm210.
18. Bellomo R., Kellum J.A., Ronco C. Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria. Intensive Care Med 2007, 33(3):409-413. 10.1007/s00134-006-0478-x.
19. LeFrock J., Ristuccia A. Teicoplanin in the treatment of bone and joint infections: an open study. J Infect Chemother 1999, 5(1):32-39. 10.1007/s101569900004.
20. Del Favero A., Patoia L., Bucaneve G., Biscarini L., Menichetti F. Leukopenia with neutropenia associated with teicoplanin therapy. DICP 1989, 23(1):45-47.
21. Wood M.J. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996, 37(2):209-222.
22. Davey P.G., Williams A.H. A review of the safety profile of teicoplanin. J Antimicrob Chemother 1991, 27(Suppl. B):69-73.
23. Gardner M.J., Altman D.G. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed) 1986, 292(6522):746-750.